ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2022

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.

S R Aravind et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.